ArticleBMC oral health2025
Key clinical and demographic factors influencing head and neck tumor severity in Lagos.
Article in BMC oral health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHead and neck tumors pose a major health challenge in Nigeria, yet the factors that influence their severity remain poorly understood. No predictive model currently exists to assess malignancy risk in this population. This study aimed to identify key clinical and demographic predictors and to develop a model for malignancy risk in tumors diagnosed in Lagos, Nigeria.
methodsWe analyzed patient records with tumor diagnoses from 2000 to 2024, obtained from the Oral and Maxillofacial Surgery and Oral Pathology departments of the Lagos University Teaching Hospital. Surgical biopsy records and corresponding histopathology reports were reviewed. Tumor sites were grouped into five anatomical regions: mandible, midface, oral mucosa and salivary glands, extra oral, and unspecified regions. Descriptive statistics summarized patient and tumor features, while statistical analyses examined associations between demographics and tumor severity (benign/malignant). A predictive model for tumor severity was developed using data-splitting and leave-one-out cross-validation approaches.
resultsOf the 1,068 patients, 1,062 had confirmed diagnoses. Median age was 35 years [IQR:23–52], 53.96% were male, and the mandible was the most common site (48.31%). Tumors were most frequent on the right (30.13%) and measured 6 × 4x2cm on average. Median duration of presentation was 12 months [IQR:5–36], with 50.75% benign tumors. Tumor severity was significantly associated with age (47 vs. 28 years), site, laterality, duration (p < 0.001), and sex (p = 0.024), with males more susceptible to malignancy. Age inversely correlated with presentation duration (p = 0.00067), and tumor site was not associated with sex (p = 0.054). Conventional ameloblastoma was the most common benign tumor, while squamous cell carcinoma was the most common malignancy. Multivariate analysis showed malignancy was associated with age (OR = 1.61; p < 0.001), tumor site (midface (OR = 3.88), oral mucosa and salivary glands (OR = 23.8), and extraoral sites (OR = 108.01) compared to the mandible [all p < 0.001]), length (OR = 1.93; p < 0.001), and shorter duration (OR = 0.68; p < 0.001). Central (OR = 0.2), left (OR = 0.46), or right laterality (OR = 0.32) lowered malignancy odds versus unspecified (all p < 0.04). Our predictive model approaches achieved area under the curve of 0.864 and 0.883.
conclusionsWe identified age, site, laterality, and duration before presentation, as key malignancy predictors. This will aid comprehensive care plans for optimal clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.